核糖体的生物合成在恶性肿瘤治疗中的研究进展

The research progress on ribosome biogenesis in malignant tumor therapy

核糖体的生物合成(ribosome biogenesis, RiBi)在细胞的生长、增殖过程中占有重要地位。随着研究的深入,RiBi被认为与恶性肿瘤的发生发展密切相关,通过干预RiBi的各个环节能够对肿瘤细胞的生长产生抑制作用。目前已有多种参与RiBi过程的因子被证明具有成为恶性肿瘤治疗靶点的潜力,此外还有RNA Pol I抑制剂的研发并投入试验,这些有望为恶性肿瘤的治疗提供新的解决方案。

Ribosome biogenesis(RiBi) plays an important role in the growth and proliferation of cell. Currently, RiBi is considered a close relationship with malignant tumor, on other hand, interfering the process of RiBi will inhibit tumor cells, which in some respects have been convinced that could be potential therapy targets. In addition, some RNA Pol I inhibitors have been developed and tested clinically.The research of RiBi may provide new therapeutic approaches for malignant therapy.